Reference medicine developed for the treatment of Parkinson’s disease becomes the market leader

2004 |

Entacapone, a drug developed by Orion Pharma’s project team, has significantly enhanced the treatment of Parkinson’s disease, a central nervous system disease resulting in, for example, shaking of the limbs, slowness of movement and muscular rigidity. The reference drug developed by Orion Pharma’s project team, has significantly enhanced the treatment of Parkinson’s disease. Picture: Juha Rahkonen

Entacapone is a patented chemical and biological innovation developed by Orion from the molecule. Using entacapone for the treatment of Parkinson’s disease in combination with levodopa significantly improves the effect of levodopa and improves the patient’s quality of life. Parkinson’s disease leads to the reduction of the neurotransmitter dopamine in the brain.